Moderna and Merck say their personalized mRNA therapy showed positive results in a major Phase 3 trial — potentially changing how America treats one of its deadliest skin cancers.
Eugene Hoshiko/AP
FILE - A local resident receives the Moderna COVID-19 vaccine shot at a center, June 30, 2021, in the Sumida ward of Tokyo.